- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.01. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | 100 | GlobeNewswire (Europe) | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) | 141 | GlobeNewswire (Europe) | Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 05.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 02.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Trading on OTCQB Market | 146 | GlobeNewswire (Europe) | Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"),... ► Artikel lesen | |
| 02.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 05.11.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing | 173 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new... ► Artikel lesen | |
| 30.10.25 | CERo Therapeutics denied Nasdaq listing, seeks OTC markets | 23 | Seeking Alpha | ||
| 30.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Receipt of Nasdaq Panel Determination | 677 | GlobeNewswire (Europe) | Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC... ► Artikel lesen | |
| 21.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML | 257 | GlobeNewswire (Europe) | Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 16.10.25 | Cero Therapeutics passt Kaufvertrag an und sichert sich 2,25 Mio. US-Dollar im ersten Closing | 4 | Investing.com Deutsch | ||
| 15.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 | 2 | GlobeNewswire (USA) | ||
| 14.10.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.10.25 | CERo Therapeutics completes first cohort in AML clinical trial | 2 | Investing.com | ||
| 13.10.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML | 236 | GlobeNewswire (Europe) | Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published... ► Artikel lesen | |
| 10.10.25 | CERo Therapeutics open to takeover offers as it awaits key data - Axios | 9 | Investing.com | ||
| 10.10.25 | CERo Therapeutics signalisiert vor wichtigen Studiendaten Verkaufsbereitschaft | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,166 | +1,55 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | ||
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,798 | -2,84 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| CAPRICOR | 19,440 | -0,51 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| CORMEDIX | 6,650 | +3,10 % | Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? | ||
| MINERVA NEUROSCIENCES | 3,360 | -7,69 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 | BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| REPLIMUNE | 6,200 | -0,80 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,130 | -1,52 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,380 | 0,00 % | Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update | - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics - - Completed $60.3 million oversubscribed private placement led by Samsara BioCapital... ► Artikel lesen | |
| IO BIOTECH | 0,326 | +4,93 % | Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals | LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 16,800 | +2,82 % | Alto Neuroscience, Inc.: Alto Neuroscience to Participate in Upcoming Investor Conferences | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| OSR HOLDINGS | 0,692 | 0,00 % | OSR Holdings, Inc.: OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries | BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment... ► Artikel lesen | |
| QIAGEN | 45,485 | -2,04 % | Aktien Frankfurt Ausblick: Kleines Minus im Dax erwartet - Qiagen weiter stark | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt bleibt auch am Mittwoch im Korrekturmodus. Nachdem sich zuletzt die Unsicherheit wegen der Zoll-Politik von US-Präsident Donald Trump wieder verstärkt... ► Artikel lesen | |
| CG ONCOLOGY | 55,10 | +3,38 % | What Analysts Are Saying About CG Oncology Stock | ||
| PRAXIS PRECISION MEDICINES | 314,75 | +7,04 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines |
Das Unternehmen CERO THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,095 Euro und damit +0,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.